Table 7.
Effect of hypertonic saline and furosemide on urinary electrolytes and proteins in two spot urinary sample after examination in a randomized, cross-over study of 24 healthy subjects
| Spot 1 (day 1 post examination) | Spot 2 (day 3–5 post examination) | |
|---|---|---|
| U-Na (mmol/L) | ||
| Placebo | 79 (41;105) | 50 (31;135) |
| Furosemide | 57 (27;98)† | 62 (32;151)* |
| U-K (mmol/L) | ||
| Placebo | 26 (15;37) | 27 (14;44) |
| Furosemide | 34 (19;52)† | 30 (17;58)* |
| U-Cl (mmol/L) | ||
| Placebo | 78 (53;126) | 63 (40;129) |
| Furosemide | 67 (38;116) | 70 (45;186) |
| U-Creatinine (mmol/L) | ||
| Placebo | 4 (3;6) | 5 (4;16) |
| Furosemide | 8 (4;13)† | 5 (3;13)* |
| U-Osmolality (mmol/L) | ||
| Placebo | 392 (200;467) | 269 (195;710)* |
| Furosemide | 430 (236;663)† | 358 (214;740)* |
| U-Albumin (mg/L) | ||
| Placebo | 2 (1;5) | 4 (2;7) |
| Furosemide | 5 (3;6)† | 4 (2;4) |
| U-ENaCγ (ng/ml) | ||
| Placebo | 0.29 (0.18;0.44) | 0.35 (0.19;0.85) |
| Furosemide | 0.57 (0.27;0.92) | 0.37 (0.21;0.92) |
| U-AQP2 (ng/ml) | ||
| Placebo | 0.40 (0.19;0.49) | 0.37 (0.26;0.81)* |
| Furosemide | 0.68 (0.27;0.95) | 0.36 (0.29;1.08)* |
| U-NGAL (ng/ml) | ||
| Placebo | 8.5 (3.8;23.8) | 9.5 (2.8;22.3)* |
| Furosemide | 19.5 (4.0;40.5) | 14.0 (3.0;25.5)* |
| U-KIM (ng/ml) | ||
| Placebo | 0.13 (0.08;0.17) | 0.22 (0.09;0.35)* |
| Furosemide | 0.40 (0.09;0.57) | 0.20 (0.08;0.49)* |
u-Na Urinary concentrations of sodium, u-K potassium, u-Cl chloride, creatinine, albumin, u-ENaCγ γ-fraction of the epithelial sodium channel, u-AQP2 aquaporin 2, u-NGAL neutrophil gelatinase-associated lipocalin and u-KIM-1 kidney injury, molecule-1. Data are shown as medians with 25 and 75 percentiles in brackets. Wilcoxon signed rank test was used to test statistically significant difference from spot 1, * = p < 0.05, and from Placebo, † = p < 0.05